Bruker Daltonics Announces that Certain Stockholders Sold Two Million Shares in a Block Trade.Business/Technology Editors BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 8, 2001 Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BDAL BDAL Battle Doll Angelic Layer (game) ) today reported that following the close of trading on November 7, 2001, four members of the Laukien Family each have sold 500,000 shares of Bruker Daltonics, or an aggregate of 2.0 million shares, in a block trade transaction handled by UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Warburg. For each selling shareholder, the number of shares sold represents approximately 5.5% of such shareholders ownership of Bruker Daltonics shares. As a result of this transaction, the public float of the Company has increased from approximately 9.4 million shares, or 17%, to approximately 11.4 million shares, or 20%, of the issued stock. Frank Laukien, the Company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , did not sell any shares. The Company's CFO See Chief Financial Officer. , John Hulburt, said: "This sale was in response to recent increased trading activity, and serves to increase the Company's public float and offer greater liquidity for its investors. The members of the Laukien family remain committed to Bruker Daltonics, but in the long run are willing to see the public ownership and public float of the Company increase." ABOUT BRUKER DALTONICS Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion